AXT 914

Drug Profile

AXT 914

Alternative Names: AXT-914

Latest Information Update: 04 Feb 2014

Price : $50

At a glance

  • Originator Novartis
  • Class Osteoporosis therapies; Quinazolines
  • Mechanism of Action Calcium-sensing receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 31 Dec 2013 Discontinued - Phase-I for Postmenopausal osteoporosis in USA (PO)
  • 31 Dec 2013 Discontinued - Phase-I for Osteoporosis in USA (PO)
  • 31 Dec 2012 No development reported - Phase-I for Postmenopausal osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top